ERBB2 and breast carcinoma: T-DM1 is increasingly used as the second-line anti-HER2 treatment since EMILIA trial showed that T-DM1 was superior to lapatinib plus capecitabine in prolonging progression-free and overall survivals, and it caused less toxicity in HER2-positive breast cancer patients previously treated with trastuzumab and a taxane [45].